Mangalam Drugs & Organics (NSE:MANGALAM) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MANGALAM Mangalam Drugs & Organics Ltd NSE:MANGALAM
43 GF Score
Price ₹27.93
GF Value ₹62.77
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics FFO per Share?

FFO per Share only applies to REITs.

NSE:MANGALAM
43GF Score
Mangalam Drugs & Organics Ltd NSE:MANGALAM
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹27.93 is trading 55.5% below its estimated GF Value™ of ₹62.77. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for NSE:MANGALAM:

  • FFO per Share:
  • GF Value™: ₹62.77 vs. price of ₹27.93 (55.5% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mangalam Drugs & Organics Business Description

Other Exchanges 532637:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
43GF Score

Get the complete analysis for NSE:MANGALAM

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹27.93
Price
₹62.77
GF Value